The US FTC conditionally clears a merger subject to divestitures in the pharmaceutical market (Amneal / Impax)

FTC Applies its Merger Remedy Best Practices and Announces a New Divestiture Principle in Recent Pharmaceutical Enforcement Action* On April 27, 2018, the Federal Trade Commission (“FTC”) announced a proposed consent agreement with Amneal Pharmaceuticals LLC (“Amneal”) and Impax Laboratories, Inc. (“Impax”) to settle charges that Amneal’s acquisition of Impax would likely harm competition in a number of generic pharmaceutical markets. [1] Under the proposed settlement, Amneal must divest Impax’s rights or assets for ten generic pharmaceutical products to three divestiture buyers: ANI Pharmaceuticals, Inc. (“ANI”), Perrigo Company plc (“Perrigo”), and G&W Laboratories (“G&W”). The FTC’s proposed consent agreement in this matter reinforces principles it announced in a recent Merger Remedies

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Weil, Gotshal & Manges (Washington)
  • Weil, Gotshal & Manges (Washington)

Quotation

Kristin Sanford, Jeff L. White, The US FTC conditionally clears a merger subject to divestitures in the pharmaceutical market (Amneal / Impax), 27 April 2018, e-Competitions Merger Remedies, Art. N° 88733

Visites 284

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues